Clinical Trial Protocol Registry
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
- Protocol number:
- Hoffmann-La Roche
- Company division:
- Official Scientific Title:
- An open label study to assess the resection rate of liver metastases following neoadjuvant therapy with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable liver metastasis
- Brief summary:
- This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable liver metastasis. Patients will receive Avastin 5mg/kg iv on day 1 of every 2 week cycle, oxaliplatin 85mg/m2 iv on day 1 of every 2 week cycle, and capecitabine 1000mg/m2 on days 1-5 and 8-12 of every 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 46.
- Study phase:
- Study type:
- Interventional; Treatment; Non-randomized; Uncontrolled; Single group; Safety/efficacy study
- Colorectal Cancer
- Intervention type:
- Intervention name:
- bevacizumab [Avastin]
- Primary outcome:
- Resection of liver metastasis after neoadjuvant treatment Time frame: Event driven
- Key secondary outcomes:
- Progression-free survival; time to disease progression Time frame: Event driven
- SAEs, specific adverse events Time frame: Throughout study
- Inclusion criteria:
- adult patients, <=75 years of age;
- chemotherapy-naive for stage IV colorectal cancer with unresectable liver metastasis;
- >=1 measurable lesion;
- ECOG status 0-2.
- Exclusion criteria:
- prior exposure to Avastin;
- clinical or radiological evidence of CNS metastases;
- uncontrolled hypertension, or clinically significant cardiovascular disease;
- ongoing treatment with aspirin (>325mg/day) or other medications known to predispose to gastrointestinal ulceration.
- Males or Females
- Age limits:
- Min: N/A Max: 75 years
- Accepts healthy volunteers:
- Anticipated start date:
- August, 2008
- Trial registration date:
- Date last updated:
For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.
- Go on the URL link- http://www.roche.com and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.
Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.
For US or global trials with US sites only, please contact the Trial Information Support Line (TISL)
- 1-888-662-6728 Monday to Friday (6am to 3pm PST)